AU6473898A - Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors - Google Patents

Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors

Info

Publication number
AU6473898A
AU6473898A AU64738/98A AU6473898A AU6473898A AU 6473898 A AU6473898 A AU 6473898A AU 64738/98 A AU64738/98 A AU 64738/98A AU 6473898 A AU6473898 A AU 6473898A AU 6473898 A AU6473898 A AU 6473898A
Authority
AU
Australia
Prior art keywords
methods
neurotrophic factor
reductase inhibitors
aldose reductase
associated activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU64738/98A
Inventor
Frank Longo
Andrew Mizisin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/045,194 external-priority patent/US6696407B1/en
Application filed by University of California filed Critical University of California
Publication of AU6473898A publication Critical patent/AU6473898A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU64738/98A 1997-03-21 1998-03-23 Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors Abandoned AU6473898A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US82210397A 1997-03-21 1997-03-21
US08822103 1997-03-21
US09/045,194 US6696407B1 (en) 1997-03-21 1998-03-20 Huntington's disease treatment comprising administering aldose reductase inhibitors to increase striatal CNTF
US09045194 1998-03-20
PCT/US1998/005623 WO1998042324A2 (en) 1997-03-21 1998-03-23 Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors

Publications (1)

Publication Number Publication Date
AU6473898A true AU6473898A (en) 1998-10-20

Family

ID=26722480

Family Applications (1)

Application Number Title Priority Date Filing Date
AU64738/98A Abandoned AU6473898A (en) 1997-03-21 1998-03-23 Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors

Country Status (2)

Country Link
AU (1) AU6473898A (en)
WO (1) WO1998042324A2 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
AU544067B2 (en) * 1981-03-02 1985-05-16 Wyeth-Ayerst Canada Inc. Thioamides and amides. treatment of diabetes
KR100194830B1 (en) * 1991-03-21 1999-06-15 빠르펭 크리스티앙 디오르 Novel derivatives of caffeic acid, orafosides, and cosmetic or pharmaceutical compositions, especially dermatological compositions containing them

Also Published As

Publication number Publication date
WO1998042324A3 (en) 1999-01-21
WO1998042324A2 (en) 1998-10-01

Similar Documents

Publication Publication Date Title
AU8030598A (en) Indole compounds as cox-2 inhibitors
AU6650198A (en) Porphyrin compounds as telomerase inhibitors
AU3106799A (en) Modulatable reflectors and methods for using same
AU8697998A (en) Proning bed
AU3867400A (en) Methods of using bioelastomers
AU1914501A (en) Split repeater
AU7473494A (en) Phase-transfer catalysis
AU1605699A (en) Substituted 3-amino-2-hydroxyphenylacetamide derivatives as enzyme inhibitors (ii)
AU7761398A (en) Hmg-coa reductase inhibitor preparation process
AU7495298A (en) Watering can
AU7450898A (en) Indole compounds
AU1922997A (en) New rolipram derivatives as camp-pde iv inhibitors
AU4789399A (en) Reactor for wood retification
AU8892698A (en) Method for methane conversion
AU9257998A (en) Method for enhancing the activity of an enzyme
AU2445997A (en) Telomerase inhibitors
AU6849798A (en) Processes and intermediates for preparing substituted indazole derivatives
AU1564701A (en) Compounds with anti-helicobacter pylori activity
AU2002306586A1 (en) Methods for modulating g2a receptor activity
AU2938997A (en) Subsituted 4-arylbutyric acid derivatives as matrix metalloprotease inhibitors
AU9173798A (en) Digester
AU6473898A (en) Methods for modulating neurotrophic factor-associated activity using aldose reductase inhibitors
AU7752698A (en) Method for the synthesis of anti-microbial hydroxybenzoats
AU1951701A (en) Methods for modulation of oocyte activation
AU1557697A (en) Method for the quantitative determination of telomerase activity